BioSpace News Archive

Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings

Conference call and webcast (in English) today, May 14, 2019 at 3:00 pm CET / 9:00 am EST

Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data

Clinical Ink is pleased to announce that Jonathan Andrus, Chief Business Officer at Clinical Ink, will receive the 2019 Excellence in Service Award from the Drug Information Association’s (DIA) Americas Regional Advisory Council.

Never-Before-Seen Integration Contextualizes Billions of Commercial Medical & Rx Claims, Empowering Users to Analyze Market Trends and Drive Business Strategies

GeoVax Labs, Inc. announced its financial results for the three months ended March 31, 2019 and provided an update on its corporate development progress.

The panel opposed approval of Daiichi Sankyo’s AML drug but supported approval for its TGCT treatment.

The trial, B7451012, evaluated abrocitinib as a monotherapy for 12 weeks. The top-line data indicated that by week 12 the proportion of patients who hit each co-primary efficacy endpoint and each key secondary endpoint with either dose, 100 mg or 200 mg, were statistically significantly higher than placebo.

The approval marks the first time the FDA has approved a checkpoint inhibitor for the treatment of advanced renal cell cancer.

“ALS is a disease you really want to make a difference in,” Toby Ferguson Biogen’s senior medical director for Neuromuscular Research and Early Development told BioSpace.